

1. [#dna Edit: Judicious succour to regulate drug pricing](#) – Daily News and Analysis

In an order that will spell relief for diabetic and heart patients, the Bombay high court has refused to stay a July 2014 notification of the National Pharmaceutical Pricing Authority (NPPA) which placed price caps on 108 single-formulation drugs used for cancer, HIV, cardiovascular, and diabetes treatment. The division bench ruled that the government was not exceeding its powers when regulating the prices as these medicines were required to be taken by the “ever increasing number of patients” throughout their life. The Indian

Pharmaceutical Alliance (IPA), a group of pharma companies, had gone to court against the notification pointing out that these drugs did not fall under the “essential” criteria and were not scheduled drugs and therefore not eligible for price control. The IPA had termed the NPPA’s action arbitrary and violative of their fundamental rights.

2. [India making a mark in pharmaceutical industry, says Nadda](#) – Business Standard

Union Health Minister J P Nadda on Wednesday said that India has made a mark in the pharmaceutical industry. Nadda, while attending a programme, said that due to affordability and quality, India posed a challenge to the western countries. The Health Minister said that his ministry is trying to strengthen the health delivery system in northeast. Nadda assured to help north eastern states in procurement and Human Resource issues in health sector.

*Similar reports-*

- [India making a mark in pharmaceutical industry, says Union Health Minister J P Nadda](#) – The Indian Express
- [India making a mark in pharmaceutical industry, says Nadda](#) – ETHealthworld.com

3. [Greater encouragement for research in naturopathy, says AYUSH min official](#) – The Times of India

Ministry of AYUSH will give greater encouragement for research in naturopathy and yogic sciences. The ministry has taken various steps to popularize traditional systems of medicine, and will support any endeavours in this regard, noted Ajith M Sharan, secretary, ministry of AYUSH at the 23rd annual convocation of Sri Dharmasthala Manjunateshwara Naturopathy and Yogic Sciences College at Ujire near here on Wednesday. Naturopathy plays an important role and is more effective in holistic treatment of individuals given its spiritual background in protecting mental and physical health. A separate department will be started in the ministry to help graduates of naturopathy register themselves, he said. Work on six proposed research centres in India including one at Nagamangala near Bengaluru has commenced. A naturopathy centre will be developed at Pune in Maharashtra, he noted.

1. [#dna Edit: Judicious succour to regulate drug pricing](#) – Daily News and Analysis
2. [India making a mark in pharmaceutical industry, says Nadda](#) – Business Standard
3. [Greater encouragement for research in naturopathy, says AYUSH min official](#) – The Times of India
4. [Domestic pharma firms facing challenging environment: Cipla](#) – The Times of India
5. [Aurobindo Pharma gets USFDA nod for injection to treat osteoporosis](#) – Mint
6. [On World Heart Day, an appeal for change](#) – The Hindu
7. [DC dept will give license to anybody who intends to become a drug trader in state: TN drug controller](#) – Pharmabiz.com

4. [Domestic pharma firms facing challenging environment: Cipla](#) – The Times of India

Pharma firm Cipla today said that environment for the domestic pharma companies remain challenging with more products coming under price control and urged the government to support the industry. "The environment for domestic pharma companies remains challenging with more products coming under price control and other pressures such as government legislation to ban certain fixed dose combination drugs," Cipla Chairman Y K Hamied told shareholders at the company's 80th annual general meeting (AGM) here. Hamied said with the tightening of new product registration procedure, the approval time to market newer products has been significantly impacted. "We do hope that the government will look into some of these challenges pragmatically to ease the operational environment for the pharma industry," he added.

*Similar report-*

- [Domestic pharma firms facing challenging environment: Cipla](#) – The Financial Express
- [Domestic pharma firms facing challenging environment: Cipla](#) – Business Standard

5. [Aurobindo Pharma gets USFDA nod for injection to treat osteoporosis](#) – Mint

Aurobindo Pharma Ltd became the latest Indian generic maker to get US Food and Drug Administration (USFDA) approval to launch zoledronic acid injection of 4 mg/5ml strength. The medicine, used to treat osteoporosis in women after menopause, is a generic version of Swiss pharmaceutical company Novartis AG's Zometa (zoledronic acid) injection. Aurobindo's zoledronic acid injection is available in a single-use vial for intravenous infusion. Aurobindo faces stiff competition from at least a dozen companies in the generic space including Indian rivals such as Dr. Reddy's Laboratories Ltd, Sun Pharma Ltd, Emcure Pharmaceuticals Ltd and Gland Pharma Ltd.

6. [On World Heart Day, an appeal for change](#) – The Hindu

The reality of life is that it does not get better by chance; it only gets better with change. I speak of change on World Heart Day (September 29) because it could well be the strongest medicine for your heart. Did you know that heart disease is reversible, that in most cases, you can change your heart health, all by yourself? Yes, with a healthier life choice, you can slash your risk of heart disease by 60 per cent. To change the world, we have to change ourselves. If each of us made a commitment to curb our excesses, be more active, and be disciplined in our diet and habits, we will experience a physical and mental awakening that will be life altering. If we aggregate this change we make as individuals, society and nations will emerge healthier and more productive.

*Similar reports-*

- [40% Delhi professionals at hypertension, diabetes risk](#) – The Times of India
- [Pre-empting cardiovascular disease in young Indians](#) – ETHealthworld.com

7. [DC dept will give license to anybody who intends to become a drug trader in state: TN drug controller](#) – Pharmabiz.com

Responding to the National Pharmaceutical Pricing Authority (NPPA)'s interference in the alleged violation of DPCO and Competition Commission Act (CC Act) by the Tamil Nadu Chemists and Druggists Association (TNCDA) and also by the manufacturers in Tamil Nadu, the drugs control administration (DCA) in Tamil Nadu has clarified that any person intends to become a drug trader will be given licence from the DC department. Director of the DCA said appointment of distributorship is carried out by the manufacturing companies and it is purely for commercial purpose, the regulatory agency has no role in it. If anybody has complaint of violation of DPCO or CCI Act, he can approach the Competition Commission of India (CCI).